Immune-mediated necrotising myopathy
Statin-associated autoimmune myositis · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
An autoimmune necrotising myopathy associated with anti-HMGCR or anti-SRP antibodies, classically triggered by statins but persisting after the drug is stopped. It causes progressive proximal weakness with markedly elevated creatine kinase and necrosis with minimal inflammation on biopsy.
Red flags
- Progressive weakness despite stopping statin
- Dysphagia or respiratory muscle involvement
- Very high CK with myoglobinuria / renal impairment
- Falling vital capacity
- Falls from proximal weakness
Assessment
Differential diagnosis
- Statin-induced self-limiting myalgia/myopathy
- Dermatomyositis / polymyositis
- Antisynthetase syndrome
- Inclusion body myositis
- Rhabdomyolysis (toxic/metabolic)
- Hypothyroid or metabolic myopathy
Investigations
- Creatine kinase (often >10x upper limit, may exceed 10,000 U/L)
- Anti-HMGCR and anti-SRP antibodies
- EMG (irritable myopathy) and MRI thigh (muscle oedema)
- Muscle biopsy (myofibre necrosis/regeneration, scant inflammation)
- Renal function and urinalysis (myoglobinuria)
- TSH and myositis antibody panel to exclude mimics
Management
- Stop the statin and withhold other myotoxic drugs
- Check renal function and hydrate if CK very high to prevent pigment nephropathy
- Confirm with anti-HMGCR/anti-SRP serology and muscle imaging/biopsy
- Recognise that weakness persists after statin withdrawal - immunosuppression is required
- Start corticosteroids as first-line treatment
- Add a steroid-sparing agent (methotrexate, azathioprine or mycophenolate) early
- Use IVIG or rituximab for severe or refractory disease (IVIG is especially useful in anti-HMGCR)
- Monitor CK and strength; provide physiotherapy and swallow assessment if bulbar involvement
Drugs & doses
Prednisolone — 0.75-1 mg/kg/day PO (up to 60 mg) with taper
IVIG — 2 g/kg total over 2-5 days (first-line adjunct in anti-HMGCR disease)
Methotrexate — 15-25 mg PO/SC once weekly with folic acid
Mycophenolate mofetil — 1 g PO BD
Rituximab — 1 g IV days 1 and 15 for refractory disease
Disposition
Admit if severe weakness, dysphagia, respiratory involvement or renal risk; otherwise urgent rheumatology for immunosuppression.
Complications & pitfalls
- Permanent muscle weakness/atrophy
- Aspiration and respiratory failure
- Pigment-induced acute kidney injury
- Treatment-related infection
- Relapse on tapering immunosuppression
Exam pearls
- Key teaching point: weakness continues or worsens after statin cessation, unlike simple statin myalgia
- Anti-HMGCR myopathy responds well to IVIG; consider it early
- CK is typically very high and tracks disease activity
- Statin exposure may be remote or absent in some anti-HMGCR cases
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.